



(12) Translation of
European patent specification

(11) NO/EP 2805720 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/575 (2006.01)
A61P 11/06 (2006.01)
A61P 19/02 (2006.01)
A61P 21/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.10.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.08.07
(86)	European Application Nr.	14173342.8
(86)	European Filing Date	2009.05.28
(87)	The European Application's Publication Date	2014.11.26
(30)	Priority	2008.05.28, US, 56715 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP2278978, 2009.05.28
(73)	Proprietor	ReveraGen BioPharma, Inc., 155 Gibbs Street, Suite 433, Rockville, MD 20850, USA
(72)	Inventor	Mccall, John, M., 3910 Warner Street, Kensington, MD 20895, USA Hoffman, Eric, 3910 Warner Street, Kensington, MD 20895, USA Kanneboyina, Nagaraju, 3910 Warner Street, Kensington, MD 20895, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge


(54)	Title	Non-hormonal steroid modulators of NF-KB for treatment of disease
(56)	References Cited:	WO-A1-2006/007910 METZINGER L ET AL: "Lazaroids enhance skeletal myogenesis in primary cultures of dystrophin-deficient mdx mice", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 126, no. 2, 1 November 1994 (1994-11- 01), pages 138-145, XP025440188, ISSN: 0022-510X, DOI: 10.1016/0022-510X(94)90263-1 [retrieved on 1994-11-01] VERNIER A ET AL: "Antioxidant lazarooids enhance differentiation of C2 skeletal muscle cells", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 186, no. 2-3, 1 January 1995 (1995-01-01), pages 177-180, XP002347343, ISSN: 0304-3940, DOI: 10.1016/0304-3940(95)11283-3

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Forbindelse VBP15 eller VBP6 for anvendelse i behandling av symptomene på muskeldystrofi, hvor nevnte forbindelser VBP15 og VBP6 har de strukturelle formler:

5



2. VBP15 eller VBP6 for anvendelse ifølge krav 1, hvor nevnte muskeldystrofi er valgt fra gruppen bestående av Duchenne muskeldystrofi, Becker muskeldystrofi, limb-girdle muskeldystrofi, medfødt muskeldystrofi, facioscapulohumeral muskeldystrofi, myoton muskeldystrofi, okulofaryngeal muskeldystrofi, distal muskeldystrofi og Emery-Dreifuss muskeldystrofi.

3. VBP15 eller VBP6 for anvendelse ifølge krav 1, hvor nevnte muskeldystrofi er Duchenne muskeldystrofi.

4. VBP15 eller VBP6 for anvendelse ifølge krav 1, hvor forbindelsen er VBP15.

5. Forbindelse for anvendelse ifølge krav 4, hvor nevnte muskeldystrofi er Duchenne muskeldystrofi.